Lipella Pharma up on completion of mid-stage bladder disease drug trial

Lipella Pharmaceuticals

16/03/2023 15:59

** Drug developer Lipella Pharmaceuticals Inc's shares
 LIPO.O  rise 37.7% to $2.5
    ** Co completes mid-stage trial evaluating the safety and
efficacy of its drug candidate LP-10 in treating hemorrhagic
cystitis
    ** Hemorrhagic cystitis is a rare diseases caused by
chemotherapy radiation, which damages the inner lining of the
bladder and causes inflammation
    ** Trial results to be presented as a late-breaking
presentation in April-end, at the American Urological
Association (AUA) annual meeting in Chicago 
    ** Study, safety and efficacy, dose and subjects response in
line with mid-stage trial data reported in January 
    ** LIPO plans to communicate with the FDA on the study's
results and the regulatory pathway ahead for LP-10
    ** Including session moves, LIPO stock has fallen 20.4% so
far in 2023; stock listed in December 2022 with IPO price of
$5.75

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))